Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
bsvZBtTdYQ5kgZXM
Écouter
